A Phase 2a, Open-Label Pilot Study to Evaluate the Safety/Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of VTX2735 in Participants with Recurrent Pericarditis

2025-524784-20-00 · tracked via the Priya Life Science EU tracker

Sponsor

Zomagen Biosciences Limited

Sponsor type

Pharmaceutical company

Therapeutic area

Cardiovascular Diseases

Decision date

27/02/2026

Enrollment target

Sites

Belgium, France, Greece

Condition studied

Recurrent Pericarditis

Eligibility

Age group

65+ years

Sex

Female, Male

Primary endpoint

Incidence and severity of AEs, SAEs, and AEs leading to study treatment discontinuation from the first dose through end of the Follow-Up Period.

Endpoint detail

Change from baseline in NRS over time through Week 6; Percent change from baseline in NRS over time through Week 6, Change from baseline in hs-CRP over time through Week 6 ; Percent change from baseline in hs-CRP over time through Week 6; Change from baseline in hs-CRP over time through Week 6 in participants with baseline CRP > 10 mg/L ; Percent change from baseline in hs-CRP over time through Week 6 in participants with baseline CRP > 10 mg/L

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-524784-20-00 on CTIS ↗ ← All trials in the EU